339 studies found for:    "primary myelofibrosis"
Show Display Options
Rank Status Study
21 Recruiting Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
Conditions: Anemia;   Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Drug: ruxolitinib phosphate;   Drug: danazol;   Other: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory biomarker analysis
22 Active, not recruiting Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Intervention: Drug: imetelstat sodium
23 Withdrawn Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
Conditions: Primary Myelofibrosis;   Primary Pulmonary Hypertension;   Secondary Myelofibrosis;   Pulmonary Arterial Hypertension
24 Completed A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)
Conditions: Myelofibrosis;   Myeloid Metaplasia
Intervention: Drug: zoledronic acid
25 Recruiting Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Conditions: Primary Myelofibrosis (PMF),;   Post-polycythemia Vera (Post-PV);   Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions: Drug: Momelotinib;   Drug: Best Available Therapy (BAT)
26 Completed Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera;   Post-Essential Thrombocytopenia
Intervention: Drug: Panobinostat
27 Active, not recruiting Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
Conditions: Primary Myelofibrosis (PMF);   Post-Polycythaemia Vera;   Essential Thrombocythaemia Myelofibrosis
Intervention: Drug: AZD1480
28 Completed Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: cyclophosphamide;   Drug: busulfan;   Drug: tacrolimus;   Drug: methotrexate;   Genetic: cytogenetic analysis;   Other: flow cytometry;   Other: pharmacological study;   Other: pharmacogenomic studies;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation
29 Recruiting A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
Condition: Primary Myelofibrosis (MF)
Intervention: Drug: Ruxolitinib
30 Active, not recruiting Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
Conditions: Primary Myelofibrosis (MF);   Post-Polycythemia Vera (PV) MF;   Post-Essential Thrombocythemia (ET) MF
Intervention: Drug: Ruxolitinib
31 Active, not recruiting
Has Results
Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence
Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide 0.5 mg;   Drug: Placebo
32 Unknown  Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis
Conditions: Myelodysplastic Syndrome;   Primary Myelofibrosis
33 Completed Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
Conditions: Essential Thrombocythemia;   Polycythemia Vera;   Primary Myelofibrosis
Interventions: Drug: tipifarnib;   Other: laboratory biomarker analysis
34 Active, not recruiting Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Agnogenic Myeloid Metaplasia;   Myelofibrosis;   Hypereosinophilic Syndrome;   Polycythemia Vera;   Mastocytosis;   Leukemia, Myelomonocytic, Chronic
Intervention: Drug: Dasatinib (BMS-354825)
35 Completed Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia
Conditions: Chronic Myeloproliferative Disorders;   Secondary Myelofibrosis
Interventions: Drug: cyclophosphamide;   Drug: prednisone;   Drug: thalidomide;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy
36 Completed Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly
Condition: Myelofibrosis
Intervention: Drug: SAR302503
37 Recruiting Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis;   PMF;   SMF;   Post-PV MF;   Post-ET MF
Intervention: Drug: INCB018424/CC-4047
38 Completed A Phase 2 Study With IPI-926 in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Fibrosis, Bone Marrow
Intervention: Drug: IPI-926
39 Completed
Has Results
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
Conditions: Essential Thrombocythemia;   Polycythemia Vera;   Primary Myelofibrosis
Interventions: Drug: lenalidomide;   Drug: prednisone;   Other: laboratory biomarker analysis
40 Recruiting A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
Condition: Primary Myelofibrosis
Intervention: Drug: Ruxolitinib

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years